Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -871.00% | -127.10% | 118.82% | -11.51% | -178.88% |
| Total Depreciation and Amortization | 0.00% | -0.06% | 0.00% | 0.12% | 0.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 808.38% | 83.76% | -209.47% | 31.46% | 417.73% |
| Change in Net Operating Assets | 110.17% | 37.22% | -349.53% | -16.48% | 360.31% |
| Cash from Operations | 136.38% | 48.16% | -69.60% | -5.84% | -131.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -95.91% | 350.65% | 967.80% | -75.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | -- | -- | 754.66% |
| Cash from Financing | -- | -100.00% | 350.65% | 361.70% | -39.38% |
| Foreign Exchange rate Adjustments | -249.69% | 78.44% | 1,614.87% | -139.31% | -41.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.12% | -132.97% | 1,620.41% | 80.20% | -122.29% |